CorMedix Inc (CRMD NASDAQ) stock market data APIs
$7.5555
0.39(5.2%)
as of May 15, 2026
Try our APIs with
free plan!
CorMedix Inc Financial Data Overview
Price chart is built with
Anychart
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Prev. Close
7.5555
Open
7.9486
High
8.2481
Low
7.4611
52 wk Range
6.125-17.43
Market Cap
592 M
P/E Ratio
3.4793
Shares Outstanding
78 452 K
Revenue
400 M
EPS
0.3495
Beta
1.458
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with CorMedix Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CorMedix Inc data using free add-ons & libraries
Get CorMedix Inc Fundamental Data
CorMedix Inc Fundamental data includes:
- Net Revenue: 400 M
- EBITDA: 229 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: 0.33
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CorMedix Inc News
New
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix Therapeutics CRMD delivered first-quarter 2026 diluted earnings of 43 cents per share, up 43.3% year over year, beating the Zacks Consensus Estimate of 35 cents. Net revenue was $127.4 milli...
CorMedix Inc. Q1 2026 Earnings Call Summary
CorMedix Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and...
CorMedix (CRMD) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATE Thursday, May 14, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Joseph Todisco Executive Vice President and Chief Operating Of...
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition
Earnings Call Insights: CorMedix (CRMD) Q1 2026 MANAGEMENT VIEW * "CorMedix is entering 2026 with strong momentum across our core priorities, delivering durable DefenCath utilization growth, advan...
Get CorMedix Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
